Rituximab — CPB 0314 | AETNA Coverage Update

Aetna modified CPB 0314 for rituximab, effective January 9, 2026. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its rituximab coverage policy under CPB 0314 Aetna's Clinical Policy Bulletin system, covering all four rituximab products: Rituxan (J9312), Truxima (Q5115), Riabni (Q5123), and Ruxience (Q5119). The update affects oncology, hematology, rheumatology, and neurology billing teams treating commercial plan members. If your practice bills any of these HCPCS codes, this policy change touches your claims.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Rituximab — CPB 0314
Policy Code	CPB 0314
Change Type	Modified
Effective Date	January 9, 2026
Impact Level	High
Specialties Affected	Oncology, Hematology, Rheumatology, Neurology, Nephrology, Transplant
Key Action	Audit your prior authorization workflows for all four rituximab products before billing under this updated policy

---

Aetna Rituximab Coverage Criteria and Medical Necessity Requirements 2026

The Aetna rituximab coverage policy under CPB 0314 covers four products: rituximab (Rituxan), rituximab-abbs (Truxima), rituximab-arrx (Riabni), and rituximab-pvvr (Ruxience). A fifth product — rituximab/hyaluronidase (Rituxan Hycela, billed as J9311) — also requires precertification but follows separate criteria.

Every single one of these products requires prior authorization. No exceptions. Call (866) 752-7021 or fax the Statement of Medical Necessity form to (888) 267-3277 before infusion. Missing that step is the fastest path to a claim denial.

Oncologic Indications

Aetna considers rituximab medically necessary for CD20-positive tumors confirmed by testing. That CD20 confirmation isn't optional — it's a hard requirement. No documentation of CD20 positivity means no medical necessity finding.

Covered oncologic diagnoses include:

Hematologic Indications

Aetna also covers rituximab as medically necessary for several non-oncologic blood disorders:

Site of Care Policy

This is the part most billing teams overlook. Aetna's Site of Care Utilization Management Policy applies to J9312, Q5115, Q5123, and Q5119. That means Aetna will scrutinize where the infusion happens, not just whether the diagnosis qualifies. Reimbursement rates and approval outcomes differ by site. Confirm your site of service aligns with Aetna's drug infusion site-of-care policy before scheduling infusions.

---

Aetna Rituximab Exclusions and Non-Covered Indications

Some CPT codes in this policy are explicitly not covered for any indication listed in CPB 0314. These aren't borderline cases — they're flat denials.

Intrathecal delivery via CPT 62350 and 62351 (implantation or repositioning of tunneled intrathecal or epidural catheters) is not covered. CPT 96450 (chemotherapy administration into CNS requiring spinal puncture) is also not covered under this bulletin. CPT 83520 (quantitative immunoassay) falls in the same category.

The real issue here is billing workflow. If a provider orders rituximab for primary CNS lymphoma — which is covered — but your team mistakenly routes chemotherapy administration through CPT 96450, the claim will deny. The diagnosis may qualify. The procedure code won't. Audit your charge capture templates for CNS cases specifically.

---

Coverage Indications at a Glance

---

Aetna Rituximab Billing Guidelines and Action Items 2026

These are the steps your team needs to take before billing under the January 9, 2026 effective date of CPB 0314.

Copy Action Items

If your practice has significant rituximab volume across multiple Aetna commercial plans, talk to your compliance officer before the January 9, 2026 effective date. The combination of site-of-care rules, biosimilar-specific coding, and CD20 documentation requirements creates real exposure if your workflows aren't aligned.

---

CPT, HCPCS, and ICD-10 Codes for Rituximab Under CPB 0314

Covered HCPCS Codes (When Selection Criteria Are Met)

CPT Codes Not Covered for Indications Listed in CPB 0314

Other CPT Codes Related to CPB 0314

These codes are part of the policy billing guidelines — primarily chemotherapy administration and related lab codes. Use the appropriate code based on the delivery method and clinical scenario.

Other HCPCS Codes Referenced in CPB 0314

These codes appear in the policy in the context of alternative or comparator therapies — primarily for MS, transplant, and rheumatologic conditions.

Key ICD-10-CM Diagnosis Codes

CPB 0314 references 1,383 ICD-10-CM codes in total. The full list is available at app.payerpolicy.org/p/aetna/0314. Map every rituximab claim to a covered diagnosis before submission — ICD-10 mismatches are a leading cause of claim denial on high-cost specialty drugs.

---